Siemens Healthineers AG (SMMNY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Siemens Healthineers AG (SMMNY) trades at $23.09 with AI Score 44/100 (Grade C). Siemens Healthineers AG develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers globally. Market cap: $25.8B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026SMMNY stock analysis for 2026: Analysts have set a consensus price target of $29.40 for Siemens Healthineers AG, suggesting 27.3% upside from the current price of $23.09. The AI MoonshotScore is 44/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SMMNY: 2/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Siemens Healthineers AG (SMMNY) Healthcare & Pipeline Overview
Siemens Healthineers AG, a subsidiary of Siemens AG, is a global leader in medical technology, offering a comprehensive portfolio of imaging, diagnostics, and advanced therapies. With a strong presence in key healthcare segments, the company serves providers worldwide, leveraging innovation to improve patient outcomes and optimize healthcare delivery.
What Is the Investment Thesis for SMMNY?
Siemens Healthineers presents a compelling investment case based on its leading market position, diverse product portfolio, and growth opportunities in the expanding healthcare technology sector. With a market capitalization of $25.8B and a P/E ratio of 18.8, the company demonstrates financial stability and profitability, supported by a gross margin of 38.4% and a profit margin of 9.1%. Key growth drivers include the increasing demand for advanced diagnostics and therapies, the aging global population, and the growing adoption of digital health solutions. The company's strong focus on innovation and strategic acquisitions, such as Varian, further enhances its growth prospects. However, investors may want to evaluate potential risks such as regulatory changes, technological disruptions, and competitive pressures from companies like CHGCY and CSLLY.
Based on FMP financials and quantitative analysis
SMMNY Key Highlights
Market capitalization of $25.8B, reflecting its significant presence in the medical devices market.
- P/E ratio of 18.8, indicating a reasonable valuation compared to its earnings.
- Gross margin of 38.4%, showcasing its ability to maintain profitability in a competitive environment.
- Profit margin of 9.1%, demonstrating efficient operations and cost management.
- Dividend yield of 2.61%, providing a steady income stream for investors.
Who Are SMMNY's Competitors?
SMMNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHGCY Chugai Pharmaceutical Co., Ltd. | $22.09 | -0.45% | $72.7B | 55 |
| CSLLY CSL Limited | $30.48 | +2.31% | $118B | 48 |
| ESLOF EssilorLuxottica S.A. | $187.69 | -0.48% | $86.3B | 47 |
| ESLOY EssilorLuxottica S.A. | $95.41 | +0.51% | $87.7B | 49 |
| FSNUY Fresenius SE & Co. KGaA | $13.64 | -0.29% | $123B | 43 |
| STE STERIS plc | $236.91 | +1.95% | $24.0B | 85 |
| DXCM DexCom, Inc. | $89.92 | +0.04% | $33.9B | 93 |
| ZBH Zimmer Biomet Holdings, Inc. | $100.72 | -0.02% | $19.5B | 78 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SMMNY's Key Strengths?
Strong market position in diagnostic imaging and in-vitro diagnostics.
- Comprehensive product portfolio and global presence.
- Innovative technology and strong R&D capabilities.
- Strategic acquisitions and partnerships.
What Are SMMNY's Weaknesses?
Exposure to regulatory changes and healthcare reforms.
- Dependence on hospital capital spending.
- Competition from established and emerging players.
- Currency fluctuations impacting international revenues.
What Could Drive SMMNY Stock Higher?
SMMNY catalyst: Expansion of digital health solutions and AI-powered diagnostics to improve patient outcomes and operational efficiency.
- Strategic partnerships and acquisitions to broaden product portfolio and market reach.
- New product launches in advanced imaging and minimally invasive therapies in Q3 2026.
- Increasing demand for healthcare services in emerging markets.
- Continued innovation in precision medicine and personalized healthcare.
What Are the Key Risks for SMMNY?
Financial-distress signal — its Altman Z-Score of 1.39 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes and healthcare reforms impacting pricing and reimbursement.
- Technological disruptions and competition from new market entrants.
- Currency fluctuations affecting international revenues and profitability.
- Product liability claims and recalls.
- Economic downturns impacting hospital capital spending and healthcare demand.
What Are the Growth Opportunities for SMMNY?
- Expansion in Emerging Markets: Siemens Healthineers has a significant opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer substantial growth potential for diagnostic imaging, in-vitro diagnostics, and advanced therapies. By tailoring its products and services to meet the specific needs of these markets, Siemens Healthineers can capture a larger share of the global healthcare market. The emerging markets healthcare sector is expected to grow at a CAGR of 8-10% over the next five years.
- Advancements in Digital Health: The increasing adoption of digital health technologies presents a significant growth opportunity for Siemens Healthineers. By leveraging its expertise in data analytics, artificial intelligence, and cloud computing, the company can develop innovative digital solutions that improve patient outcomes, enhance operational efficiency, and reduce healthcare costs.
- Strategic Acquisitions and Partnerships: Siemens Healthineers can drive growth through strategic acquisitions and partnerships that expand its product portfolio, enhance its technological capabilities, and strengthen its market position. The acquisition of Varian Medical Systems in 2021 is a prime example of this strategy, enabling Siemens Healthineers to become a leader in cancer care solutions. By continuing to pursue strategic M&A opportunities, the company can accelerate its growth and create long-term value for shareholders. The healthcare M&A market is expected to remain active in the coming years, driven by factors such as industry consolidation and technological disruption.
- Focus on Precision Medicine: The growing trend towards precision medicine, which involves tailoring medical treatment to the individual characteristics of each patient, presents a significant growth opportunity for Siemens Healthineers. By developing advanced diagnostic tools and therapies that enable personalized treatment decisions, the company can improve patient outcomes and reduce healthcare costs. The precision medicine market is projected to reach $140 billion by 2027, driven by factors such as the increasing availability of genomic data, the development of targeted therapies, and the growing adoption of personalized healthcare approaches.
- Innovation in Minimally Invasive Procedures: Siemens Healthineers can capitalize on the increasing demand for minimally invasive procedures by developing innovative technologies that enable surgeons to perform complex operations with greater precision and less trauma to the patient. The company's Advanced Therapies segment is well-positioned to benefit from this trend, offering a range of products that support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The minimally invasive surgery market is projected to reach $40 billion by 2028, driven by factors such as the increasing prevalence of chronic diseases, the aging population, and the growing demand for less invasive surgical techniques.
What Are SMMNY's Competitive Advantages?
- Strong brand reputation and global presence.
- Comprehensive product portfolio spanning imaging, diagnostics, and therapies.
- Extensive installed base of medical equipment.
- Significant investment in research and development.
- Strategic acquisitions, such as Varian Medical Systems, enhance market position.
What Does SMMNY Do?
Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft, is a global leader in medical technology, empowering healthcare providers to increase value by expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare. Founded in Erlangen, Germany, the company has evolved from a component of Siemens into a separately managed entity focused exclusively on healthcare. Siemens Healthineers operates through four key segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides a wide array of medical imaging solutions, including magnetic resonance imaging (MRI), computed tomography (CT), X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services for laboratory, molecular, and point-of-care diagnostics, along with workflow solutions and informatics products. The Varian segment, acquired in 2021, focuses on cancer care technologies and solutions, providing oncology departments with technology-enabled workflows, clinical services, and digital solutions for managing treatment and therapy. The Advanced Therapies segment provides products designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery, including angiography systems and mobile C-arms. Siemens Healthineers also offers a range of services, including equipment performance management, clinical education, asset management, and consulting services, serving healthcare facilities globally.
What Products and Services Does SMMNY Offer?
- Develops and manufactures diagnostic imaging systems, including MRI, CT, X-ray, and ultrasound.
- Provides in-vitro diagnostic products and services for laboratory, molecular, and point-of-care testing.
- Offers cancer care technologies and solutions for oncology departments.
- Develops advanced therapies for image-guided minimally invasive treatments.
- Provides workflow solutions for laboratories and informatics products.
- Offers equipment performance management and clinical education services.
- Provides asset management and managed departmental services for healthcare facilities.
- Offers consulting and digital health services.
How Does SMMNY Make Money?
- Sells diagnostic and therapeutic products and services to healthcare providers.
- Generates revenue through equipment sales, service contracts, and consumables.
- Provides software and digital solutions for healthcare management.
- Offers consulting services to optimize healthcare operations.
What Industry Does SMMNY Operate In?
Siemens Healthineers operates in the medical devices industry, which is characterized by continuous innovation, increasing regulatory scrutiny, and growing demand for advanced healthcare solutions. The global medical devices market is projected to reach $600 billion by 2026, driven by factors such as the aging population, rising prevalence of chronic diseases, and technological advancements. The competitive landscape includes major players like CHGCY (Canon Medical Systems), CSLLY (Koninklijke Philips), and ESLOF (FUJIFILM Holdings). Siemens Healthineers differentiates itself through its comprehensive product portfolio, strong brand reputation, and global presence, positioning it well to capitalize on the industry's growth opportunities.
Who Are SMMNY's Key Customers?
- Hospitals and clinics
- Diagnostic laboratories
- Research institutions
- Private medical practices
- Government healthcare agencies
Company Profile
Siemens Healthineers AG operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Forchheim, DE. The company is led by CEO Bernhard Montag. SMMNY has traded publicly since 2018.
Key Financial Metrics
Return on equity for Siemens Healthineers AG stands at 12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.8%, showing how much profit it generates from its asset base. SMMNY trades at a trailing price-to-earnings ratio of 18.76, below the Healthcare sector average of ~23x. Its free cash flow yield is 5.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.1%, the inverse of the P/E and a quick read on earnings relative to price.
SMMNY Valuation & Market Position
With a $25.8B market cap, Siemens Healthineers AG sits in the large-cap segment of the market. Relative to its peer group, SMMNY's quantitative score of 44/100 is roughly in line with the peer average of 48/100.
Quarterly Financial Performance: Siemens Healthineers AG
Revenue for Siemens Healthineers AG came in at $5.76B during Q2 2026. The company recorded net income of $669.0M, with diluted EPS of $0.30. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SMMNY averaged $0.22 in diluted EPS.
Financial Health
Siemens Healthineers AG's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.39 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Siemens Healthineers AG has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.8% above estimates on average.
Forward Outlook
Wall Street analysts project Siemens Healthineers AG revenue of about $23.76B for fiscal 2026, with EPS near $1.15. The estimate reflects 19 contributing analysts.
SMMNY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in strong upcoming performance.
- Community sentiment has leaned positively, with discussions highlighting innovative product launches that could drive growth.
- Market perception is bolstered by strong demand for healthcare technology, particularly in diagnostic imaging and lab diagnostics.
- Positive analyst commentary has emerged, focusing on Siemens Healthineers' strategic positioning in the expanding healthcare sector.
Bear Case
- Concerns about potential supply chain disruptions have surfaced, which could impact production and delivery timelines.
- Some community members express skepticism about the sustainability of growth amidst increasing competition in the healthcare technology space.
- Recent regulatory challenges in key markets have raised caution among investors, making them wary of future profitability.
- Market sentiment has shown volatility, with discussions reflecting uncertainty around global economic conditions affecting healthcare spending.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $5.76B | $669M | $0.30 |
| Q1 2026 | $5.77B | $514M | $0.12 |
| Q4 2025 | $5.35B | $446M | $0.20 |
| Q3 2025 | $4.98B | $587M | $0.26 |
Based on FMP financials and quantitative analysis
SMMNY Latest News
-
Siemens Healthineers AG (SMMNY) Discusses Q3 Pre-Close Updates: Foreign Exchange and Tariff Impacts on Revenue and Earnings Prepared Remarks Transcript
seekingalpha.com · Jun 26, 2026
-
The 4th China International Supply Chain Expo: Healthy Life Chain Unveils Full Spectrum of Global Healthcare Supply Chain Innovation
Yahoo! Finance: SMMNY News · Jun 25, 2026
SMMNY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SMMNY.
Price Targets
Consensus target: $29.40
SMMNY MoonshotScore
What does this score mean?
The MoonshotScore rates SMMNY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Siemens Healthineers AG (SMMNY) Discusses Q3 Pre-Close Updates: Foreign Exchange and Tariff Impacts on Revenue and Earnings Prepared Remarks Transcript
The 4th China International Supply Chain Expo: Healthy Life Chain Unveils Full Spectrum of Global Healthcare Supply Chain Innovation
Leadership: Bernhard Montag
CEO
Bernhard Montag has served as the CEO of Siemens Healthineers since 2015. He joined Siemens in 1995 and has held various leadership positions within the company, including Head of Strategy and Head of the Healthcare Imaging division. Montag holds a degree in electrical engineering from the University of Erlangen-Nuremberg and an MBA from INSEAD.
Track Record: Under Bernhard Montag's leadership, Siemens Healthineers has successfully executed its strategic vision, including the acquisition of Varian Medical Systems and the expansion of its digital health offerings. He has overseen significant growth in revenue and profitability, as well as the company's successful IPO in 2018. Montag has focused on driving innovation and customer centricity, positioning Siemens Healthineers as a leader in the healthcare technology industry.
Siemens Healthineers AG ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate that represents shares of a foreign company trading on U.S. stock exchanges. SMMNY is traded as a Level 1 ADR, meaning it trades over-the-counter (OTC) and has less stringent reporting requirements than listed stocks. This allows U.S. investors to invest in Siemens Healthineers AG without directly dealing with foreign exchanges.
- Home Market Ticker: Frankfurt Stock Exchange (XETRA), Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SMMN
SMMNY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that Siemens Healthineers AG (SMMNY) has limited regulatory oversight and reporting requirements compared to companies listed on exchanges like the NYSE or NASDAQ. Companies in this tier may not meet minimum financial standards or have chosen not to comply with stricter listing requirements, potentially increasing investment risk due to less transparency and oversight.
- OTC Tier: OTC Other
- Limited regulatory oversight and reporting requirements.
- Potential for information asymmetry and lack of transparency.
- Lower trading volumes and liquidity compared to listed stocks.
- Increased risk of fraud or manipulation.
- Greater price volatility due to limited market participation.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and ownership.
- Research any legal or regulatory issues involving the company.
- Consult with a financial advisor or legal professional.
- Subsidiary of a reputable parent company (Siemens AG).
- Established business operations and track record.
- Presence in a regulated industry (healthcare).
- Availability of some financial information, even if limited.
- Active investor relations or corporate communications.
Common Questions About SMMNY (Healthcare)
What does the AI Score mean for SMMNY?
SMMNY holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Siemens Healthineers AG develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers globally. The company operates through four segments …
What does Siemens Healthineers AG do?
Siemens Healthineers AG is a global medical technology company that develops, manufactures, and sells a wide range of diagnostic and therapeutic products and services to healthcare providers. Its offerings include imaging systems (MRI, CT, X-ray, ultrasound), in-vitro diagnostics, cancer care technologies, and advanced therapies for minimally invasive procedures.
What do analysts say about SMMNY stock?
Analyst consensus on SMMNY stock is generally positive, reflecting the company's strong market position, diverse product portfolio, and growth opportunities in the healthcare technology sector. Key valuation metrics, such as P/E ratio and dividend yield, are considered reasonable compared to industry peers.
What are the main risks for SMMNY?
The main risks for Siemens Healthineers AG include regulatory changes and healthcare reforms that could impact pricing and reimbursement, technological disruptions and competition from new market entrants, currency fluctuations affecting international revenues and profitability, product liability claims and recalls, and economic downturns impacting hospital capital spending and healthcare demand. These risks could negatively affect the company's financial performance and market valuation.
What are the key growth opportunities for SMMNY in healthcare?
Siemens Healthineers AG has several key growth opportunities in the healthcare sector, including expansion into emerging markets with rapidly increasing healthcare spending, advancements in digital health technologies such as AI-powered diagnostics and remote patient monitoring, strategic acquisitions and partnerships to broaden its product portfolio and market reach, a focus on precision medicine to enable personalized treatment decisions, and innovation in minimally invasive procedures to meet the growing demand for less invasive surgical techniques.
How does Siemens Healthineers AG manage patent expiration risks?
Siemens Healthineers AG manages patent expiration risks through a combination of strategies, including continuous innovation to develop new products and technologies, lifecycle management of existing products to extend their market exclusivity, strategic patenting to protect its intellectual property, and diversification of its product portfolio to reduce dependence on any single product or technology.
What are the key factors to evaluate for SMMNY?
Siemens Healthineers AG (SMMNY) holds an AI score of 44/100 (low). P/E: 18.8x vs the S&P 500's ~20-25x. Analysts target $29.40 (+27%). Not financial advice.
How frequently does SMMNY data refresh on this page?
SMMNY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SMMNY's recent stock price performance?
Siemens Healthineers AG (SMMNY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in diagnostic imaging and in-vitro diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for SMMNY may provide further insights.
- OTC market data may have limited availability and reliability.